PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

PHARMApharmadossier

Topic

IL-17 Inhibitor

Secukinumab, ixekizumab, bimekizumab, IL-17 pathway positioning, payer access, and immunology competition.

2 articles·Lives underPricing & Access Specialty·Last updated 2026-06-19

Evidence· June 19, 2026 · 13 min read

IL-17 and IL-23 biologics in FAERS: 400,283 adverse-event reports by the numbers

By Ran Chen#Real-World Evidence #Label Warnings #Postmarketing Requirements

Evidence· June 13, 2026 · 11 min read

EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy

By Ran Chen#Immunology #Clinical Evidence #Pivotal Trials